Sugi Predict

Sugi Predict / Compounds / SCHEMBL19034

SCHEMBL19034

SCHEMBL19034

Cc1oncc1C(=O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.61
▸ NPC1 O15118 5/20 0.61
▸ RAB9A P51151 5/20 0.61
▸ HTT P42858 2/20 0.61
▸ NPSR1 Q6W5P4 2/20 0.61
▸ TP53 P04637 2/20 0.61
▸ GMNN O75496 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ CYP1A2 P05177 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ HTR1A P08908 1/20 0.61
▸ THRB P10828 1/20 0.61
▸ PIM1 P11309 1/20 0.61
▸ CYP2C9 P11712 1/20 0.61
▸ MAOA P21397 1/20 0.61
▸ SLC6A2 P23975 1/20 0.61
▸ HTR2A P28223 1/20 0.61
▸ AGTR1 P30556 1/20 0.61
▸ CCKBR P32239 1/20 0.61
▸ MC4R P32245 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29625262 1.00 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL19402549 0.82 CSF1R (0.69) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL11319574 0.81 RAB9A (0.45) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL30107111 0.80 HTT (0.44) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL24047119 0.80 HTT (0.44) SMN1; SMN2NPC1RAB9AHTTNPSR1
Leflunomide SCHEMBL7650952 0.78 DHODH (0.61) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL11429250 0.78 RAB9A (0.63) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL8489376 0.78 LMNA (0.49) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL9182578 0.77 RAB9A (0.69) SMN1; SMN2NPC1RAB9AHTTNPSR1
SCHEMBL11319571 0.76 RAB9A (0.48) SMN1; SMN2NPC1RAB9AHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805945-B1 Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors MSD ITALIA SRL (IT) 2019-04-03 — — EP claimed
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. 2014-10-09 — — US claimed
US-8779171-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2014-07-15 — — US claimed
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2013-06-06 — — US claimed
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-14 — — US disclosed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 — — EP disclosed
US-12595262-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 — — US disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 — — US disclosed
US-12583871-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-03-24 — — US disclosed
US-12552826-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-02-17 — — US disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-12516321-B2 RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) SIRNA THERAPEUTICS, INC. (US) 2026-01-06 — — US disclosed
US-6306874-B1 ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. MERCK & CO., INC. 2001-10-23 — — US disclosed
WO-2001062252-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-08-30 — — WO disclosed
WO-2001062251-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-08-30 — — WO disclosed
US-6245759-B1 PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS MERCK & CO., INC. 2001-06-12 — — US disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 — — WO disclosed
WO-2001029025-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-04-26 — — WO disclosed
WO-2001017995-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-03-15 — — WO disclosed
WO-2000053605-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2000-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 SMN1; SMN2 118/4885NPC1 1410/4885RAB9A 3390/4885
US-20130142758-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 SMN1; SMN2 4315/4885NPC1 1924/4885RAB9A 4301/4885
US-20140301976-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 SMN1; SMN2 4315/4885NPC1 1924/4885RAB9A 4301/4885
US-12595262-B2 PRMT5 inhibitors PRMT1, PRMT5, CARM1 SMN1; SMN2 331/4885NPC1 4089/4885RAB9A 4052/4885
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF TOP1, NCL, NOLC1 SMN1; SMN2 958/4885NPC1 226/4885RAB9A 2571/4885
US-12583871-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 SMN1; SMN2 90/4885NPC1 2758/4885RAB9A 2176/4885
US-12552826-B2 PRMT5 inhibitors PRMT5, PRMT6, PRMT1 SMN1; SMN2 206/4885NPC1 1546/4885RAB9A 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.